Filing Flows › Immunocore Holdings (IMCR) › Q3 2026 › vs Q2 2026
Immunocore Holdings (IMCR) Q3 2026 vs Q2 2026 (quarter over quarter)
Immunocore Holdings's revenue fell $13.7M (-12%) from $116M in Q2 2026 to $102M in Q3 2026.
Immunocore Holdings, Q3 2026: revenue $102M (-1% year over year), operating margin -13.3%, net loss $14.2M, operating cash flow $20.1M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 17.4% | 13.1% | +4.3 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $102M | $116M | −$13.7M | -12% |
| Net loss | $14.2M | $808K | $13.4M | 18× |
| Costs & expenses | $116M | $119M | −$2.8M | -2% |
| Operating costs | $116M | $119M | −$3.1M | -3% |
| Interest & other, net | $460K | −$2.5M | $2.9M | — |
| Income tax | $153K | $294K | −$141K | -48% |
| Cost of revenue | $676K | $1.1M | −$412K | -38% |
| Research & development | $74.7M | $73.9M | $758K | +1% |
| SG&A | $40.5M | $43.9M | −$3.4M | -8% |
| Operating cash sources | $34.3M | $16.7M | $17.6M | +105% |
| Depreciation | $1.1M | $1.0M | $80K | +8% |
| Share-based compensation | $9.7M | $9.4M | $326K | +3% |
| Working capital & other | $23.5M | $6.3M | $17.2M | +272% |
| Net loss absorbed | $14.2M | $808K | $13.4M | 18× |
| Operating cash flow | $20.1M | $15.9M | $4.2M | +26% |
| Free cash flow (OCF − capex) | $17.7M | $15.1M | $2.6M | +17% |
| Capital expenditures | $2.3M | $786K | $1.6M | +198% |
Questions
How much did Immunocore Holdings's revenue grow quarter over quarter in Q3 2026?
Immunocore Holdings's revenue fell $13.7M (-12%) from $116M in Q2 2026 to $102M in Q3 2026.